Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 100.00% is 216% above its 5-year average of 31.63%, near the high end of its 5-year range (-414.65%–100.00%).
As of the fiscal period ended Tuesday, June 30, 2026. In line with its 12-month average of 100.00%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
100.00%
GROSS MARGIN AVG TTM
100.00%
GROSS MARGIN AVG 3Y
100.00%
GROSS MARGIN AVG 5Y
31.63%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
0.00%
CURRENT VS 3Y AVG
0.00%
CURRENT VS 5Y AVG
+216.19%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.76%
median of 627 covered companies
CURRENT VS SECTOR MEDIAN
+139.46%
vs the sector median at left
Market Cap
$998.42M
Gross Margin
79.71%
TTM Avg
80.13%
3Y Avg
81.57%
5Y Avg
-49.18%
Market Cap
$1.02B
Gross Margin
53.74%
TTM Avg
53.23%
3Y Avg
56.54%
5Y Avg
58.23%
Market Cap
$1.02B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
16.67%
Market Cap
$1.02B
Gross Margin
11.80%
TTM Avg
10.80%
3Y Avg
10.72%
5Y Avg
10.72%
Market Cap
$986.27M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
50.00%
5Y Avg
50.00%
Market Cap
$985.37M
Gross Margin
97.19%
TTM Avg
61.28%
3Y Avg
80.64%
5Y Avg
87.09%
Market Cap
$982.03M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immatics N.V. (IMTX) | $1.01B | 100.00% | 100.00% | 100.00% | 31.63% |
| Janux Therapeutics, Inc. (JANX)vs › | $998.42M | 79.71% | 80.13% | 81.57% | -49.18% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $997.34M | N/A | N/A | N/A | N/A |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.02B | 53.74% | 53.23% | 56.54% | 58.23% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.02B | 0.00% | 0.00% | 0.00% | 16.67% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | 11.80% | 10.80% | 10.72% | 10.72% |
| Aktis Oncology, Inc. (AKTS)vs › | $986.27M | 100.00% | 100.00% | 50.00% | 50.00% |
| MeiraGTx Holdings plc (MGTX)vs › | $985.37M | 97.19% | 61.28% | 80.64% | 87.09% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.03M | 0.00% | 0.00% | 0.00% | 0.00% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | 77.26% | 80.62% | 79.35% | 80.86% |
Gross Margin
100.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 100.00% |
| 2025-12-31 | 100.00% |
| 2025-09-30 | 100.00% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | 100.00% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | 100.00% |
| 2023-12-31 | 100.00% |
| 2023-09-30 | -414.65% |
| 2023-06-30 | -7.52% |
| 2023-03-31 | -181.55% |
| 2022-12-31 | 26.04% |
| 2022-09-30 | -89.72% |
| 2022-06-30 | -46.48% |
| 2022-03-31 | 75.57% |
| 2021-12-31 | -46.00% |
| 2021-09-30 | -229.43% |
| 2021-06-30 | -291.98% |
| 2021-03-31 | -211.35% |
| 2020-12-31 | -120.72% |
| 2020-09-30 | -122.14% |
| 2020-06-30 | -74.09% |
| 2020-03-31 | -73.95% |
| 2019-12-31 | -176.62% |
| 2019-09-30 | -102.39% |
| 2019-06-30 | -80.94% |
| 2019-03-31 | -120.35% |
| 2018-12-31 | 100.00% |
| 2018-09-30 | 100.00% |
| 2018-06-30 | 100.00% |
| 2018-03-31 | 100.00% |
